An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction
- 31 December 2006
- journal article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 169 (6), 2236-2244
- https://doi.org/10.2353/ajpath.2006.060398
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Decreased Endomyocardial RANKL Expression in Transplant Coronary Artery DiseaseTransplantation, 2006
- Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone statusActa Endocrinologica, 2005
- Coronary calcification in hemodialysis patients: The contribution of traditional and uremia-related risk factorsKidney International, 2005
- Endothelial inflammation in insulin resistanceThe Lancet, 2005
- Endothelial inflammation in insulin resistanceThe Lancet, 2005
- Prognostic value of osteoprotegerin in heart failure after acute myocardial infarctionJournal of the American College of Cardiology, 2004
- A Stable Prostacyclin Analogue Reduces High Serum TNF-α Levels in Diabetic PatientsExperimental and Clinical Endocrinology & Diabetes, 2004
- Vascular Endothelial Growth Factor Up-regulates Expression of Receptor Activator of NF-κB (RANK) in Endothelial CellsPublished by Elsevier BV ,2003
- RANKL regulates endothelial cell survival through the phosphatidylinositol 3′‐kinase/Akt signal transduction pathwayThe FASEB Journal, 2003
- Nonsteroidal anti‐inflammatory drugs prevent early diabetic retinopathy via TNF‐α suppressionThe FASEB Journal, 2002